...
首页> 外文期刊>Chemical and Pharmaceutical Bulletin >Conversion of Ginsenoside Rb1 into Six Types of Highly Bioactive Ginsenoside Rg3 and Its Derivatives by FeCl3 Catalysis
【24h】

Conversion of Ginsenoside Rb1 into Six Types of Highly Bioactive Ginsenoside Rg3 and Its Derivatives by FeCl3 Catalysis

机译:FeCl3催化将人参皂苷Rb1转化为六种高生物活性人参皂苷Rg3及其衍生物

获取原文
           

摘要

Ginsenoside Rb1 is an important saponin of ginseng(s); however, Rb1, with 3- O - and 20- O -sugar moieties, has low bioavailability. Here, we report the derivatization of ginsenoside Rb1 to completely generate six types of highly bioactive minor ginsenoside Rg3 and its derivatives by FeCl3 catalysis, the reaction conditions are similar to enzymatic reaction conditions. In FeCl3 catalysis, the only 20- O -sugar-moiety of ginsenoside Rb1 was decomposed into the minor ginsenosides Rk1 and Rg5 with newly produced C-20 ethylene bands; but also hydrolyzed into 20( S )-Rg3 and 20( R )-Rg3; subsequently the C-24(25) ethylene bands of 20( S )-Rg3 and 20( R )-Rg3 were hydrated to 20( S )-25-OH-Rg3 and 20( R )-25-OH-Rg3. After separation of reaction mixture from 34?g ginsenoside-Rb1 by silica-gel-column, the 3.3?g sample I of TLC top-band consisting of Rg5 and Rk1, 8.7?g sample II of TLC middle-band consisting of 20( S )-Rg3 and 20( R )-Rg3, 3.5?g sample III of TLC bottom-band consisting of unknown product-I and -II including 20( S )-25-OH-Rg3, were obtained. The sample III consisting of unknown product-I and -II was purified by crystallization, and identified to 20( S )-25-OH-Rg3 and 20( R )-25-OH-Rg3 by HPLC-Evaporative Light Scattering Detector (ELSD) and NMR. Therefore, six types of minor-ginsenosides Rk1, Rg5, 20( S )-Rg3, 20( R )-Rg3, 20( S )-25-OH-Rg3 and 20( R )-25-OH-Rg3 were successfully prepared from ginsenoside Rb1 by FeCl3 catalysis. FeCl3 has low toxicity and is inexpensive, and the reaction conditions are similar to enzymatic reaction conditions; thus, this method is applicable to the development of ginseng-based drugs.
机译:人参皂甙Rb1是人参的重要皂苷;然而,具有3-O-和20-O-糖部分的Rb1具有较低的生物利用度。在这里,我们报道人参皂苷Rb1的衍生化通过FeCl 3 催化完全生成六种类型的高生物活性次要人参皂苷Rg3及其衍生物,反应条件与酶促反应条件相似。在FeCl 3 催化下,人参皂甙Rb1的仅有20-O-糖基被分解为具有新产生的C-20乙烯带的次要人参皂甙Rk1和Rg5。但也水解成20(S)-Rg3和20(R)-Rg3;随后将20(S)-Rg3和20(R)-Rg3的C-24(25)乙烯带水合为20(S)-25-OH-Rg3和20(R)-25-OH-Rg3。用硅胶柱从34μg人参皂苷-Rb1中分离出反应混合物后,由Rg5和Rk1组成的TLC顶带的3.3μg样品I,由20(得到3.5μg的由未知产物-I和-II组成的TLC底带的样品S)-Rg3和20(R)-Rg3,其中包括20(S)-25-OH-Rg3。通过结晶纯化由未知产物-I和-II组成的样品III,并通过HPLC-蒸发光散射检测器(ELSD)鉴定为20(S)-25-OH-Rg3和20(R)-25-OH-Rg3 )和NMR。因此,成功制备了六种类型的次人参皂甙Rk1,Rg5、20(S)-Rg3、20(R)-Rg3、20(S)-25-OH-Rg3和20(R -25-25-OH-Rg3)。 FeCl 3 催化从人参皂苷Rb1中提取FeCl 3 毒性低,价格便宜,反应条件与酶促反应条件相似。因此,该方法适用于人参类药物的开发。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号